1. Home
  2. ETON vs GMRE Comparison

ETON vs GMRE Comparison

Compare ETON & GMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eton Pharmaceuticals Inc.

ETON

Eton Pharmaceuticals Inc.

HOLD

Current Price

$16.27

Market Cap

498.8M

Sector

Health Care

ML Signal

HOLD

Logo Global Medical REIT Inc.

GMRE

Global Medical REIT Inc.

HOLD

Current Price

$33.84

Market Cap

449.5M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETON
GMRE
Founded
2017
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
498.8M
449.5M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ETON
GMRE
Price
$16.27
$33.84
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$29.67
$40.50
AVG Volume (30 Days)
211.3K
124.2K
Earning Date
11-06-2025
11-04-2025
Dividend Yield
N/A
8.85%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$70,316,000.00
$144,829,000.00
Revenue This Year
$107.23
$7.49
Revenue Next Year
$29.72
$3.18
P/E Ratio
N/A
N/A
Revenue Growth
102.77
6.04
52 Week Low
$11.09
$29.05
52 Week High
$23.00
$45.75

Technical Indicators

Market Signals
Indicator
ETON
GMRE
Relative Strength Index (RSI) 45.11 53.00
Support Level $16.53 $32.90
Resistance Level $17.33 $34.09
Average True Range (ATR) 0.64 0.60
MACD 0.08 -0.21
Stochastic Oscillator 32.91 32.41

Price Performance

Historical Comparison
ETON
GMRE

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

About GMRE Global Medical REIT Inc.

Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.

Share on Social Networks: